Floppy baby syndrome is a condition associated with impaired development of motor skills and signs of hypotonia, profound weakness, and rag-doll features. 1, 2 Because numerous disorders can give rise to such symptoms, the diagnosis of the underlying cause of floppy baby syndrome can be complex and problematic. For effective management of these infants, it is critical that all potential causes are examined as early in the course of disease as possible.
Pompe disease, also known as glycogen storage disease type II or acid maltase deficiency was the first described lysosomal storage disease (LSD). It is an uncommon cause of floppy baby syndrome, and is thus often overlooked in early differential diagnoses of infants. It is caused by a deficiency in the lysosomal enzyme acid alpha glucosidase. Recent clinical trials using enzyme replacement therapy have highlighted the importance of early diagnosis of Pompe patients as a determinant factor in therapeutic outcomes. [3] [4] [5] [6] [7] This article represents a consensus expert view on the diagnostic challenges of Pompe disease. The diagnostic algorithm and the review of the differential diagnoses of infantile hypotonia provided in this article should help pediatricians to identify Pompe disease and optimize potential treatment approaches.
PATHOPHYSIOLOGY
Pompe disease is an autosomal recessive disorder caused by a deficiency of the enzyme acid alpha glucosidase (GAA), which results in lysosomal accumulation of glycogen in multiple organs with prominent involvement of heart and skeletal muscle. 8, 9 The clinical presentation is heterogeneous, largely due to the amount of residual GAA enzyme activity associated with different mutations in the GAA gene. 10 Thus, Pompe disease varies with respect to age at onset, disease progression, and extent of organ involvement. 11 Pompe disease may be considered a member of several disease families, and is thus known by several names including glycogen storage disease-II (GSD-II), glycogenosis (type II), and acid maltase deficiency (AMD). 11 However, since alpha glucosidase hydrolyzes both glycogen and maltose, AMD may not be as accurate a term as the others. 12 There is a spectrum of clinical presentations of Pompe disease, with the infantile form as a rather well-defined clinical phenotype that is the most severe end of the disease spectrum.
Classic infantile Pompe disease presents within the first year of life and progresses rapidly. Symptoms are severe due to massive amounts of glycogen accumulation in tissues throughout the body; death typically occurs by the age of 1 year due to either cardiac and/or respiratory failure. 13, 14 Glycogen accumulation in the lysosomes of muscle tissue disrupts muscle fiber structure and function, and infants subsequently present with floppy baby syndrome. In variant form, the disease may present in childhood, adolescence, or adulthood, and is more slowly progressive. 11 In contrast to classic infantile Pompe disease, respiratory, not cardiorespiratory, failure is the major cause of death.
On clinical examination, infants with Pompe disease have hypotonia with the classic head lag when they are lifted from a supine position. They have the tendency to slip through when being held up during examination. Major motor and neurolgic milestones such as rolling over, sitting, crawling, or standing are often delayed, not reached, or lost after being reached. In the late stages of the disease, babies are often flaccid and in a frog leg position. Feeding difficulties, as well as poor sucking and swallowing, lead to a significant failure to thrive. Many patients require tube feeding. Facial features include macroglossia, open mouth, low facial muscle tone, wide open eyes, and poor control of oral secretions with pooling. They also have poor suck and swallow reflexes, and in the late stages exhibit diminished gag reflexes and deep tendon reflexes, and sometimes ankle clonus can be elicited. Muscles frequently feel firm due to glycogen accumulation, particularly the gastrocnemius muscle, often with the appearance of a pseudohypertrophy. On evaluation of respiration, there is an increased respiratory rate (due to progressive cardiac failure) or underlying respiratory infection. Use of accessory muscles of respiration, such as intercostal and subcostal muscles, is evident. Nasal flaring may be observed. Reduced breath sounds are usually detected in the left lower lobe due to left mainstem bronchus compression from left ventricular hypertrophy. Moderate hepatomegaly is often present. Cardiac exam often reveals a murmur or gallop. When in heart failure, the extremities may be somewhat cool and clammy. The skin is difficult to pick up and feels taut and stretched (balloon-like).
Electrocardiograms (EKG) in Pompe patients show high Rwave voltages as well as a characteristic short P-R interval indicative of accelerated atrioventricular conduction. 15 Intracardiac EP studies have not been done in patients but studies in a mouse model of Pompe disease demonstrate a short A-H interval. 16 The echocardiogram is also distinctive in Pompe disease, showing a left-ventricular mass index that is significantly greater than the 95 th percentile by Z-score. In later stages of the disease the left lung is significantly compressed by the enlargement of the heart, and the right lung may also be affected when the heart crosses the midline.
Laboratory testing of infants with Pompe disease reveals elevations in CK, aldolase, alanine transaminase (ALT), aspartate transaminase (AST), and lactate dehydrogenase (LDH). The ALT and AST usually represent the muscle fraction. Oligosaccharides, specifically a glucose tetrasaccharide, are also elevated in urine and plasma. An EMG shows a myopathic pattern, but it is not helpful in coming to a conclusive diagnosis. Muscle biopsy shows the lysosomal accumulation of glycogen and disruption of muscle fibers. Although the chest x-ray and EKG findings are highly suggestive of Pompe disease, the final diagnosis is established after measuring the activity of the GAA enzyme in skin fibroblasts or muscle. However, deficient endogenous GAA activity can also be assessed rapidly in peripheral blood mononuclear cells under specific conditions. Assays carried out with whole leukocytes are not reliable because of the potential cross-contamination with the residual activity of neutral maltases at an acid pH. 13 Though peripheral blood mononuclear cells do not provide an accurate quantitative measure of enzyme activity, they are preferred to whole leukocytes for screening. 13 Recent assays using tandem mass spectrometry on dried blood spots will likely prove useful for newborn screening. 17 
EPIDEMIOLOGY
Pompe disease is a rare disorder, thus few epidemiologic studies have been performed to date. The incidence of infantile-and late-onset forms of Pompe disease has been estimated at 1 in 138,000 births and 1 in 57,000 births, respectively. The overall incidence of Pompe disease is estimated at 1 in 40,000. 18 -20 Pompe disease is transmitted as an autosomal recessive trait and, therefore, affects males and females with equal frequency. In a study of 20 Dutch classic infantile cases and 133 cases reported in the literature, the distribution according to gender was 41% male and 52% female, while the sex was unknown in the remaining 7% of cases, all of which were reported in the literature. 21 Overall, the symptoms of the classic infantile form of Pompe disease started at a median age of 1.6 months. The diagnosis was made at a median of 5.3 months in the Dutch cases and 4.5 months in the published cases. The Dutch patients died at a median age of 6 months, and those in the other published cases died at 7.7 months. None of the Dutch patients reached their first birthday, whereas 11 (8%) patients in the published cases survived beyond 12 months, although only 2 patients reached 18 months of age. The first symptoms that were noted most frequently were feeding difficulties and failure to thrive, which were seen in nearly half of the cases. Other common initial symptoms were motor development delays, respiratory problems, and cardiac problems. 14 
CLINICAL PRESENTATIONS
On a routine physical exam of an infant with subtle signs of developmental delay, an astute pediatrician may hear a heart murmur or gallop rhythm, which can lead to further work-up and diagnosis. Parents also often report easy fatigue and sweating during feeding. On occasion, a child may present with a supraventricular tachycardia and other arrhythmic disturbances.
On the basis of clinical experience, infants with Pompe disease may present for pulmonary, neurological, gastrointestinal, or cardiac reasons (Fig. 1 ). In the classic pulmonary presentation, there are frequent upper respiratory tract infections which are treated with antibiotics. When a satisfactory treatment response is not obtained, a chest x-ray is often ordered to look for underlying pneumonia showing massive cardiomegaly. Alternatively, a child may present with respiratory insufficiency due to repeated infections. CO 2 retention may be found when blood gases or clinical chemistries are analyzed, prompting further evaluation.
In a neurological presentation, parents bring their child to the pediatrician with concerns regarding development typically at about 3-4 months of age. The child may be referred to a pediatric neurologist due to concerns of severe hypotonia and developmental delay. In some cases, a diagnosis of mitochondrial disease is considered, because of the multisystemic nature of organ involvement (cardiomegaly, hepatomegaly, hypotonia) in which these disorders may present. Alternatively, an infant may come to clinical attention following loss of previously achieved milestones.
Gastrointestinal symptoms include a failure to thrive, difficulty with feeding, poor sucking responses, pooling of food and saliva, and occasionally gastroesophageal reflux. On further evaluation, a diagnosis of Pompe disease is made.
In a cardiovascular presentation, infants may present for routine elective surgery such as a hernia repair, and are diagnosed with Pompe disease following a rhythm disturbance during routine anesthesia. These infants are at greatly increased risk of cardiac complications, including death, during anesthesia. 13 A number of considerations that should be taken into account when administering anesthesia to this patient population have been reviewed. 22 On follow-up, a diagnosis of infantile Pompe disease can usually be made following an echocardiograph, chest x-ray, and subsequent electrocardiogram (EKG), though milder Pompe disease usually does not cause cardiac enlargement. A chest x-ray is often the easiest screening test to obtain in a pediatric office. Infants with Pompe disease show pronounced cardiac hypertrophy and enlargement, often with loss of lung volume in the left lower base due to left mainstem bronchus compression. The EKG is distinctive, with a short P-R interval (due to short atrioventricular conduction time), high R-wave voltages across the precordium and limb leads, as well as fast atrioventricular conduction, tall and large QRS complexes, and inverted T-waves (or repolarization disturbances). These findings are pathognomonic for Pompe disease.
Finally, infants may present with evidence of GAA deficiency in a direct enzymatic assay, performed due to a family history of a sibling with Pompe disease or a sibling death in which an autopsy revealed evidence of an enlarged heart and presence of storage material.
DIFFERENTIAL DIAGNOSIS Initial hypotonia
Initial symptoms of Pompe disease are always consistent with hypotonia. A proper diagnosis of Pompe, however, requires the exclusion of several other more common disorders that share a similar presentation (Table 1) . 1, 13, 23, 24 Normal muscle tone (postural and phasic), or the amount of resistance to movement in a muscle, is required for babies to reach important milestones (head holding, crawling, and sitting) during the first year (Fig. 2) , 25 and is an important component when examining the motor development of infants. Hypotonia is defined as a reduction in postural tone (e.g., response to gravity) with or without alterations in phasic tone (i.e., tendon reflexes). Infants with hypotonia present with a flaccid appearance, decreased resistance to passive manipulation of limbs with head held in a midline position, head lag upon arm traction, slipping through on vertical suspension, and draping over when suspended horizontally. Hypotonia without significant weakness may indicate a systemic disorder, a chromosomal abnormality, or a connective tissue disorder; those causes should therefore be excluded before performing neurological studies (Fig. 3) .
Defining particular anatomic characteristics: Pompe disease versus other conditions
Hypotonia may be central when it results from pathology involving the central nervous system (CNS), or peripheral when its cause involves the lower motor unit (anterior horn cells, peripheral nerve, neuromuscular junction, and muscle fiber), or both (Fig. 4) . Relatively few features require consideration to distinguish a central abnormality from a peripheral disorder; a retrospective review of 50 cases of neonatal hypotonia identified a central etiology, most commonly hypoxic/ ischemic encephalopathy in two thirds of patients. 26 In certain cases, however, central and lower motor unit abnormalities coexist (Fig. 5 ).
In infants with central hypotonia, the prenatal or perinatal history may be consistent with a CNS insult. The developmental delay is usually global, and includes a lack of normal social and adaptive responses and marginal degrees of weakness. Seizures, microcephaly, dysmorphic features, and malformation of the brain or other organs may also occur. Tendon reflexes are normal or brisk, and brisk and/or persistent infantile reflexes may be present. Movement can be triggered via postural reflexes. Examination of cerebrospinal fluid (CSF), electromyography (EMG), nerve conduction parameters, muscle biopsy, or serum enzymes usually do not reveal abnormalities. Brain imaging studies (computed tomography or magnetic resonance imaging) are useful for diagnosing hypoxic-ischemic encephalopathy, ventricular bleeds, and white/gray matter abnormalities.
Pompe disease can be considered a peripheral hypotonia. The primary observation in infants with peripheral hypotonia is usually a gross motor developmental delay, with normal social and adaptive responses. Specific parts of the lower motor unit may be affected, including anterior horn cells, peripheral nerve, neuromuscular junction, and the muscle itself (Fig. 5) . The degree of weakness is proportional to, or in excess of, the degree of peripheral hypotonia and is usually not uniform across muscles. 27 Noninvasive measures (chest x-ray, EKG, creatine kinase (CK), aldolase, lactate dehydrogenase, and liver enzymes) and specific tests such as EMG, nerve conduction studies, or muscle biopsy, can be carried out to determine whether the disorder is one of the nerve, neuromuscular junction, or muscle. 28 These are some of the key clinical findings for conditions that are part of the differential diagnosis for Pompe disease:
• In disorders affecting the spinal cord or anterior horn cell, such as Werdnig-Hoffman disease (and, of historical note, poliomyelitis), the hypotonia is usually accompanied by generalized weakness, absent reflexes, and fasciculations especially of the tongue. Serum muscle enzyme levels are usually normal or slightly elevated, with no sensory function and CSF abnormalities. An EMG reveals larger, fewer motor units firing rapidly in association with widespread fibrillation potentials. Muscle biopsy demonstrates marked fascicular atrophy of muscle fibers. The diagnosis can be confirmed by mutation analysis of the SMN gene on chromosome 5.
• For peripheral nerve disorders such as Guillian-Barre syndrome, elevated CSF protein levels may occur. An EMG exhibits slowing of motor and sensory nerve conduction and low compound muscle action potentials with low or absent sensory nerve action potentials. Muscle biopsy shows signs of denervation, and nerve biopsy shows predominant hypomyelination or amyelination frequently without onion-bulb formation.
• Neuromuscular junction disorders, such as myasthenia gravis, are characterized by weakness involving the face, eyelids, and extraocular muscles, and EMG-confirmed decremental responses to repetitive motor nerve stimulation. Muscle stretch reflexes, sensory function, and serum enzyme activity derived from muscle and CSF protein levels are often normal.
Primary muscle diseases are characterized by severe weakness, often in the proximal muscle groups of the extremities. The face typically appears long and expressionless and is involved in several childhood disorders, including: Pompe disease, Steinert disease (i.e., congenital myotonic dystrophy), congenital muscular dystrophies, and mitochondrial myopathies. In hypotonic muscle disorders, muscle stretch reflexes are depressed in proportion to the degree of weakness, with no fasciculations, or sensory or CSF abnormalities. Serum muscle enzyme concentrations may be elevated, but are often not detectable in slowly progressive disorders. EMG shows myopathic changes and distinctive abnormalities like myotonia, whereas muscle biopsy demonstrates diagnostic abnormalities in central cores, mitochondria, nemaline rods, myotubular fibers with large centrally placed nuclei, muscle fiber size, and abnormal increases in storage material with concomitant disruption of muscle fibers.
IMPORTANCE OF EARLY DIAGNOSIS FOR POMPE DISEASE
Early diagnosis of the cause of floppy baby syndrome is critical because some disorders may be treatable (Table 2) . Pediatricians and primary care physicians should be encouraged to initiate a diagnostic work-up rather than take a "wait and see" approach when an infant presents with early developmental delays. In Pompe disease, ERT with recombinant human GAA (rhGAA) is in clinical investigation and may become more widely available, but it must be initiated early to maximize benefits. [3] [4] [5] [6] [7] This recombinant protein replaces cellular glycogen content and clears glycogen from lysosomes. 28 Clinical studies show that it reduces heart size and maintains normal cardiac function, improves muscle tone, and in some cases may improve motor and neurological development, and prolong survival. 29 In the most recent studies investigating rhGAA obtained from Chinese hamster ovary cells, heart size decreased and cardiac function improved in all patients; no matter what the stage of the disease. 5 All infants in these studies survived past the critical age of 1 year, in some cases remaining ventilator-free, while displaying noticeable motor improvement. 5 These preliminary results consistently show that the best responses are associated with earlier initiation of ERT. 5 In vitro studies with adenovirus-mediated transfer of the alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from pa- tients with Pompe disease leads to high level expression of deficient enzyme and corrects glycogen accumulation in these cells. 30 Similarly, in Prader-Willi syndrome, growth hormone replacement therapy is considered an essential component in patient management. 31 In addition to accelerating growth, growth hormone has been shown to increase muscle mass and decrease body fat. Growth hormone treatment improves strength of both skeletal and respiratory muscles with reduction of the number of apnea and hypopnea events. 32, 33 In other disorders, symptomatic interventions may be available that can help infants developmentally. For example, neonatal myasthenia, presenting either as transient disease due to maternal autoimmune myasthenia gravis or in congenital myasthenic syndromes, can be helped by supportive care and agents such as Mestinon® (pyridostigmine bromide). Similarly, supportive care and treatment are also available in infantile botulism. 34 In this disorder, infants usually do well for several months and then have constipation before hypotonia develops with cranial nerve involvement. These infants have sluggish pupillary responses, dilated pupils, dysphagia, and weakness descending from the head to the extremities. Another condition that needs to be considered is a carnitine transporter defect. Low levels of carnitine can cause infants to present with cardiomyopathy and subsequent respiratory failure. Treatment is simple, with carnitine supplements reversing symptoms. Even in disorders where treatment is not available, early diagnosis is important for providing parents with realistic information about their child's prognosis and to provide appropriate genetic counseling for recurrence risks.
An early opportunity for diagnosing floppy baby syndrome may exist during the prenatal period. In high-risk pregnancies, a level 2 ultrasound is considered an appropriate level of screening. The ultrasound should provide a view of all four chambers of the heart, and if grossly abnormal, should lead to a referral for a fetal echocardiogram. If hypertrophic cardiomyopathy is detected, then Pompe disease needs to be considered as a possible diagnosis. Although not conclusive, it would alert pediatricians of the need for a complete diagnostic work-up shortly after delivery. Pompe disease can also be diagnosed prenatally via enzyme analysis on chorionic villi or amniocytes. Mutation analysis during the first trimester is another way that floppy baby syndrome may first be detected. For Pompe disease, such screening would only be likely when there is a family history of the disease and the specific mutation for the family is identified.
CONCLUSION
Pediatricians play a central role in the diagnosis of Pompe disease. Unfortunately, due to the rarity of the disorder, it is often misdiagnosed for more common disorders with similar symptoms. To properly diagnose Pompe disease, clues about the anatomic level of the underlying abnormality and the likely pathology should be obtained from a medical history and physical examination. Based on these findings, further work-up or referral to a specialist should also be considered to eliminate other disorders that lead to the development of floppy baby syndrome. Pediatricians should particularly focus on Pompe disease when a chest x-ray shows evidence of an enlarged heart and an EKG shows a short P-R interval. Early diagnosis is critical, as enzyme replacement therapies under investigation 
